Two Sigma Investments, LP Aravive, Inc. Transaction History

Two Sigma Investments, LP

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$1.25 - $1.92 $115,732 - $177,765	-92,586 Reduced 71.77%	36,426 $45,000
Q1 2023 May 15, 2023	BUY	$1.29 - $2.46 $3,079 - $5,872	2,387 Added 1.89%	129,012 $258,000
Q4 2022 Feb 14, 2023	BUY	$1.2 - $1.83 $151,950 - $231,723	126,625 New	126,625 $167,000
Q2 2022 Aug 15, 2022	SELL	$0.93 - $1.9 $33,499 - $68,439	-36,021 Reduced 70.73%	14,907 $15,000
Q1 2022 May 16, 2022	SELL	$1.85 - $2.75 $89,784 - $133,463	-48,532 Reduced 48.8%	50,928 $98,000
Q4 2021 Feb 14, 2022	SELL	$2.19 - $4.07 $22,773 - $42,323	-10,399 Reduced 9.47%	99,460 $218,000
Q3 2021 Nov 15, 2021	SELL	$3.67 - $5.8 $202,224 - $319,591	-55,102 Reduced 33.4%	109,859 $409,000
Q2 2021 Aug 16, 2021	SELL	$4.65 - $6.42 $305,398 - $421,646	-65,677 Reduced 28.48%	164,961 $986,000
Q1 2021 May 17, 2021	BUY	$5.11 - $9.24 $301,070 - $544,402	58,918 Added 34.31%	230,638 $1.52 Million
Q4 2020 Feb 16, 2021	BUY	$4.36 - $6.51 $136,389 - $203,645	31,282 Added 22.27%	171,720 $969,000
Q3 2020 Nov 16, 2020	BUY	$4.7 - $12.06 $283,645 - $727,821	60,350 Added 75.35%	140,438 $660,000
Q2 2020 Aug 14, 2020	SELL	$5.18 - $14.81 $250,074 - $714,982	-48,277 Reduced 37.61%	80,088 $932,000
Q1 2020 May 15, 2020	SELL	$3.5 - $13.77 $82,015 - $322,672	-23,433 Reduced 15.44%	128,365 $739,000
Q4 2019 Feb 14, 2020	BUY	$6.21 - $14.02 $942,665 - $2.13 Million	151,798 New	151,798 $2.08 Million
Q1 2019 May 15, 2019	SELL	$3.35 - $8.27 $117,762 - $290,715	-35,153 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$3.23 - $8.7 $113,544 - $305,831	35,153 New	35,153 $124,000

28.1K

Ticker ARAV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 30,518,300
Description
Aravive, Inc., a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of pl...

Get notified when there are updates to the investment portfolio of Two Sigma Investments, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Investments, LP with notifications on news.